Norepinephrine Dopamine Reuptake Inhibitors (NDRIs) are drugs that function by inhibiting the reuptake of the neurotransmitters norepinephrine and dopamine. This leads to increased neural concentrations of these activating neurotransmitters, resulting in increased stimulation of the central nervous system. Certain NDRIs inhibit reuptake of norepinephrine to a greater extent than dopamine (and vice versa). Others may have …
Norepinephrine Reuptake Inhibitors (NRIs) are drugs that function primarily by inhibiting the reuptake of the neurotransmitter norepinephrine (noradrenaline) and/or epinephrine (adrenaline). Inhibiting the reuptake of norepinephrine tends to elicit stimulating effects, thereby increasing both cortical arousal and energy levels. The NRI drugs are typically prescribed to individuals that may benefit from increased arousal such as …
In recent years, biotech and pharmaceutical companies have been developing new classes of antidepressants. These new classes attempt to improve on older classes of medication in regards to efficacy, side effects, and tolerability. One such class that is being developed is that which targets opioid receptors, particularly the kappa receptor. These drugs are classified as …
Individuals diagnosed with major depression often are found to have reduced volume within their hippocampus. The hippocampus is a small region of the brain that is responsible for regulating various memory and spatial navigation functions. It is also believed to play a pivotal role in the regulation of mood. Modern day antidepressants such as SSRIs …
The quest to come up with a superior antidepressant is in full effect among biotech and pharmaceutical companies. Although there are some companies that are still tweaking various formulations of serotonergic, noradrenergic, and dopaminergic substances (e.g. triple reuptake inhibitors) others are thinking outside the box. Based on current trends, the next decade or two of …
Scientists and mental health researchers have long been collecting evidence to discover what causes depression. Their goal is to find a specific neurotransmitter or system that could be targeted to develop a new class of antidepressant medication that would be more effective for the masses, result in less side effects, and be considered safe. While …
NRX-1074 is a new antidepressant under development by the biotech company Naurex. It is this same company that has already been granted “fast track” status by the FDA for their intravenous antidepressant GLYX-13 – which shows significant promise. Naurex’s private stock has been steadily rising due to emergence of preliminary evidence suggesting that both of …